About DGI
Diploid Genomics, Inc. (DGI) is building a new foundation for precision health—uniting phased diploid genome sequencing with multimodal clinical data and advanced AI to help detect disease earlier, predict risk more accurately, and guide more personalized care.
Today’s sequencing and health data pipelines leave critical signal behind: important heritable variation—more than 60%—can be missed, and imaging, clinical records, and genomics are rarely analyzed together. DGI is designed to close that gap, turning high-resolution biology into practical, clinician-ready insight.
We’re building an integrated, multimodal precision health record that brings together phased diploid genomes, imaging, and clinical data—and a research engine that converts those data into validated diagnostics, biomarkers, and next-generation AI models.
Capture. Integrate. Deliver.
We sequence complete, phased diploid genomes to capture variation that conventional approaches can miss. Multimodal analytics then connects genotype, imaging, and longitudinal clinical phenotypes. Through our clinical-grade operational backbone the data is then translated into discoveries providing actionable decision support.
Built for Partnership
We collaborate with healthcare systems, specialty clinics, biopharma, diagnostics companies, and academic partners to validate discoveries, accelerate clinical utility, responsibly expand diverse datasets, and bring our technology to individuals. If you’re interested in partnering, we’d like to talk.
Executive Leadership
J. Craig Venter, PhD
Co-Founder and Chief Executive Officer
Founder, chair, and CEO of the J. Craig Venter Institute, Dr. Venter is a pioneering genomic scientist whose work transformed DNA sequencing and synthetic biology. He led landmark efforts to sequence the first human genome, developed whole‑genome shotgun sequencing, and created the first synthetic cell, and later founded Human Longevity, Inc. to advance precision, pre‑symptomatic medicine.
Anders Dale, PhD
Co-Founder and Chief Technology Officer
President of the J. Craig Venter Institute and professor, Dr. Dale is a leader in advanced neuroimaging and data science. His work focuses on multimodal brain imaging and the integration of quantitative imaging with genomic and health data to predict outcomes, alongside his roles as professor emeritus at UC San Diego and founder of Cortechs Labs.
Gene Myers, PhD
Chief Scientific Officer
Gene Myers is a computer scientist and biotechnologist renowned for foundational algorithms that enabled modern genome sequencing and analysis. He created BLAST, pioneered string‑graph genome assembly, and led large‑scale genome reconstruction and imaging initiatives across genomics and developmental biology, with appointments spanning UC Berkeley, Celera Genomics, HHMI, and the Max Planck Society.
Scientific Advisory Board
Sam Levy, PhD
Chief scientific officer at ClearNote Health, Dr. Levy is a genomics and epigenomics expert focused on translating molecular biomarkers into early cancer detection tests. He has led development of 5‑hydroxymethylcytosine–based diagnostics and held senior scientific roles at Celera, Genomic Health, and multiple biotech startups, alongside academic appointments at J. Craig Venter Institute and Scripps.
Lisa Madlensky, PhD
Dr. Madlensky is a board‑certified genetic counselor specializing in cancer risk assessment, prevention, and family‑based care for hereditary cancer syndromes. Her research advances clinical genetic testing, public health implementation, and quality‑of‑life outcomes, and she directs the Family Cancer Genetics Program at UC San Diego Moores Cancer Center.
Silvio Gutkind, PhD
Dr. Gutkind is an internationally recognized leader in cancer signaling and precision immunotherapy, known for pioneering discoveries in G‑protein and GPCR‑driven tumor biology. He serves as distinguished professor and chair of pharmacology at UC San Diego, and as associate director for Basic Science at the Moores Cancer Center.
Stephen W. Scherer, PhD, DSC, FRSC
Dr. Scherer is a genomic scientist whose research has defined the role of structural variation in human disease, particularly autism spectrum disorders. He leads major translational genomics initiatives as chief of research at SickKids and holds senior academic leadership roles at the University of Toronto.
Robert C. Green, MD, MPH
Dr. Green is an internationally recognized leader in genomics and precision medicine whose work has advanced the responsible integration of genomic information into clinical care worldwide. He is professor of medicine (genetics) at Harvard Medical School and directs the Genomes2People research program at Mass General Brigham, the Broad Institute, and Ariadne Labs.